Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)

Delayed Quote. Delayed  - 08/29 05:35:02 pm
73.5 EUR   +0.30%
04:23p DAIICHI SANKYO : Antiepileptic lacosamide filed for partial amendmen..
08/19 UCB : Transparency notification
08/18 UCB : Transparency notification
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
08/23/2016 08/24/2016 08/25/2016 08/26/2016 08/29/2016 Date
73(c) 72.9(c) 72.03(c) 73.28(c) 73.5(c) Last
255 424 139 522 217 320 359 498 207 161 Volume
0.00% -0.14% -1.19% +1.74% +0.30% Change
More quotes
Financials (€)
Sales 2016 4 047 M
EBIT 2016 736 M
Net income 2016 458 M
Debt 2016 992 M
Yield 2016 1,73%
Sales 2017 4 324 M
EBIT 2017 899 M
Net income 2017 563 M
Debt 2017 637 M
Yield 2017 1,84%
P/E ratio 2016 28,48
P/E ratio 2017 23,01
EV / Sales2016 3,77x
EV / Sales2017 3,44x
Capitalization 14 253 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products for central nervous system and immunology disorders under the Cimzia, Xyzal, Zyrtec, Tussionex, Lortab, Vimpat, Keppra and Neupro.The company was founded by... 
Sector
Pharmaceuticals
Calendar
10/25Earnings Release
More about the company
Surperformance© ratings of UCB
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB
04:23p DAIICHI SANKYO : Antiepileptic lacosamide filed for partial amendment of approva..
08/19 UCB : Transparency notification
08/18 UCB : Transparency notification
08/14 UCB : U.S. District Court confirms validity of patent for UCB's Vimpat®
08/05 AMPHASTAR PHARMACEUTICALS : Purchases International Medication Systems (UK) Limi..
07/28 UCB : continues to deliver on its growth strategy
07/25 AMGEN : UCB and Amgen submit biologics license application for Romosozumab to th..
07/05 DAIICHI SANKYO : UCB and Daiichi Sankyo will jointly commercialize lacosamide in..
07/04 UCB : and Daiichi Sankyo announce Japanese approval of lacosamide (brand name VI..
06/10 UCB : bimekizumab demonstrates positive results in early development in patients..
More news
Sector news : Pharmaceuticals - NEC
03:05p Mylan to launch generic EpiPen at half the price of original
01:56pDJMYLAN : Feeling Heat on EpiPen Price, Will Offer Cheaper Generic
11:29aDJROCHE : Receives US FDA Emergency Use Authorization for Zika Test -- Update
11:10aDJROCHE : Receives US FDA Emergency Use Authorization for Zika Test
09:29aDJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/31 UCB S.A. 2016 Q1 - Results - Earnings Call Slides
07/31 UCB's (UCBJF) CEO Jean-Christophe Tellier on Q2 2016 Results - Earnings Call ..
07/22 Amgen submits BLA in U.S. for osteoporosis candidate romosozumab
05/28 LANNETT : Structural Benefits Of The Kremers Acquisition: 100+% Upside
03/21 Amgen's romosozumab successful in late-stage study in men with osteoporosis
Advertisement
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 78,8 €
Spread / Average Target 7,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Gerhard N. Mayr Chairman
Mark D. McDade Chief Operating Officer & Executive Vice President
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Loew-Friedrich Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB-11.95%15 957
JOHNSON & JOHNSON15.89%325 679
ROCHE HOLDING LTD.-12.84%214 671
PFIZER INC.7.87%211 206
NOVARTIS AG-10.83%210 234
ASTRAZENECA PLC7.33%173 797
More Results